The firm demonstrates a persistent inability to fund operations internally, reporting a negative free cash flow margin of -30.7% in 2025Q3.
| Cash from Operations | -4.23M | -10.01M | -3.82M | -2.66M | -1.01M | -5.52K |
| Operating CF Margin % | - | -60.3% | -22.91% | -27.03% | -39.62% | - |
| Operating CF Growth % | -553.45% | -161.88% | -43.73% | -163.21% | -18196.38% | - |
| Net Income | -11.94M | -14.26M | -14.79M | -4.91M | -1.33M | -5.52K |
| Depreciation & Amortization | 1.42M | 1.67M | 1.41M | 609.59K | 83.91K | 0 |
| Stock-Based Compensation | 0 | 23.65K | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.31M | 5.01M | 6.6M | 1.1M | 21.04K | 0 |
| Working Capital Changes | 2.98M | -2.44M | 2.96M | 548.81K | 216.15K | 0 |
| Change in Receivables | 86.85K | 172.21K | 125.62K | -233.9K | -228.12K | 0 |
| Change in Inventory | 105.98K | 12.42K | 84.91K | -230.13K | -41K | 0 |
| Change in Payables | -373.32K | -1.23M | 2.19M | 974.04K | 44.89K | 0 |
| Cash from Investing | -1.96M | -237.98K | -1.87M | -14.67M | -4.02M | 0 |
| Capital Expenditures | -108.14K | -237.98K | -383.73K | -134.97K | -1.31M | 0 |
| CapEx % of Revenue | 0.7% | 1.43% | 2.3% | 1.37% | 51.41% | - |
| Acquisitions | 0 | 0 | -1.49M | -14.51M | -2.66M | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | -1.85M | 0 | 0 | -20.02K | -51.25K | 0 |
| Cash from Financing | 5.89M | 10.59M | 5.63M | 15.71M | 7.07M | 269.16K |
| Debt Issued (Net) | 327.43K | -3.65M | 185.44K | 15.97M | 6.84M | 0 |
| Equity Issued (Net) | 2M | 1000K | 1000K | 0 | 385K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -650K | 0 | 0 | 0 | 0 |
| Other Financing | 500K | 4M | 1 | -260.61K | -162.73K | 269.16K |
| Net Change in Cash | -304.95K | 344.73K | -65.29K | -1.61M | 2.04M | 263.64K |
| Free Cash Flow | -4.34M | -10.24M | -4.2M | -2.84M | -2.32M | -5.52K |
| FCF Margin % | -27.9% | -61.74% | -25.21% | -28.83% | -91.03% | - |
| FCF Growth % | 57.89% | -143.64% | -48.3% | -22.18% | -41937.54% | - |
| FCF per Share | -0.71 | -1.85 | -1570.60 | -634.53 | -519.35 | -1.24 |
| FCF Conversion (FCF/Net Income) | 0.36x | 0.70x | 0.26x | 0.54x | 0.76x | 1.00x |
| Interest Paid | 826.78K | 1.55M | 188.95K | 239.43K | 80.2K | 0 |
| Taxes Paid | 0 | 0 | 0 | 192.14K | 0 | 0 |
Imminent liquidity and solvency
According to recent financial disclosures, IVP's operating cash flow consistently trails net losses, with the OCF/NI ratio fluctuating wildly, including a 0.51 reading in 2025Q3, which suggests that the company's reported net losses are not being mitigated by non-cash charges or meaningful working capital improvements.
The persistent gap between net income and operating cash flow indicates that the company is struggling to convert its service-based revenue into actual liquidity. Investors should monitor this divergence, as it suggests that the underlying clinic operations are not generating the cash necessary to cover corporate-level overhead.
As reported in quarterly filings, IVP has failed to achieve positive free cash flow in nine of the last ten quarters, with FCF margins reaching a low of -156.4% in 2024Q3, signaling a structural inability to fund operations through internal cash generation.
The consistent negative FCF trajectory implies that the company remains entirely dependent on external financing to sustain its current footprint. This trend warrants further investigation into how long the company can maintain operations without significant capital injections or a radical shift in its cost structure.
Based on the provided cash flow statements, working capital changes have been highly erratic, swinging from a $2.1M inflow in 2024Q4 to a $3.9M outflow in 2024Q3, which suggests that the company lacks a stable or predictable cycle for managing its payables and receivables.
Such volatility in working capital often indicates operational friction, potentially stemming from difficulties in managing vendor relationships or collecting payments from clients. This instability appears to exacerbate the company's liquidity constraints, making it difficult to forecast cash needs with any degree of certainty.
As noted in recent financial statements, IVP's CapEx/Revenue ratio has remained consistently low, dropping to 1.0% in 2025Q3, which may indicate that the company is deferring necessary maintenance or technology upgrades to preserve its dwindling cash reserves.
While low capital intensity might appear favorable in a cash-constrained environment, it may also suggest that the company is failing to invest in the equipment or infrastructure required to remain competitive. This strategy appears to be a short-term survival tactic that could compromise long-term service quality.
Quick answers to the most common questions about buying IVP stock.
Inspire Veterinary Partners, Inc. (IVP) generated $-10.0M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Inspire Veterinary Partners, Inc. (IVP) reported negative free cash flow of $10.2M in 2024, indicating capital requirements exceeded cash from operations.
Inspire Veterinary Partners, Inc. (IVP) spent $0.2M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, Inspire Veterinary Partners, Inc. (IVP) spent $0.7M on share repurchases. This shows the company's commitment to returning capital to its equity investors.